Drug Profile


Alternative Names: RWJ 53308

Latest Information Update: 11 Oct 2006

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Class Antiplatelets; Small molecules; Vascular disorder therapies
  • Mechanism of Action GPIIb-IIIa antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Myocardial infarction; Thrombosis

Most Recent Events

  • 06 Sep 2000 Elarofiban is the generic name for RWJ 53308
  • 28 Aug 2000 Phase-II clinical trials for Myocardial infarction in World (PO)
  • 28 Aug 2000 Phase-II clinical trials for Myocardial infarction in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top